Metabolic Abnormalities, Genetic and Behavioral Risk Factors for Hypertension among Patients Attending Bafoussam Regional Hospital, Cameroon

Vanessa Linda Nzesseu¹, Charles Kouam Kouam², Jean-de-Dieu Tamokou^1, and Jules-Roger Kuiate¹

¹Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon

²Department of Internal Medicine, Bafoussam Regional Hospital, Bafoussam, Cameroon

Cite this paper:
Vanessa Linda Nzesseu, Charles Kouam Kouam, Jean-de-Dieu Tamokou and Jules-Roger Kuiate. Metabolic Abnormalities, Genetic and Behavioral Risk Factors for Hypertension among Patients Attending Bafoussam Regional Hospital, Cameroon. American Journal of Medical Sciences and Medicine. 2020; 8(5):169-179. doi: 10.12691/ajmsm-8-5-2

Abstract

Background: Hypertension is one of the most public health problems worldwide. More than 60% of the risk factors for hypertension are associated with metabolic disturbances. Literature perusal showed lack of information regarding the risk factors for hypertension in people from the West Region of Cameroon. Therefore, the present study was intended to evaluate the metabolic abnormalities and risk factors for hypertension in patients attending the Bafoussam Regional Hospital in Cameroon. Methods: A cross-sectional and descriptive study was conducted within the Bafoussam Regional Hospital on 343 individuals (99 normotensives and 244 hypertensives). Genetic and behavioral risk factors for hypertension were determined through a questionnaire. Hypertension was diagnosed by measuring blood pressure. Cardiac, renal and hepatic biochemical parameters were analysed in blood and urine by methods resulting from commercial kits. Results: Smoking (24.2%), advanced age (90.1%), obesity (33.6%), sedentary lifestyle (56.1%), family history of hypertension (63.9%), hypertriglyceridemia (20.5%), hyperglycemia (36.9%), hypernatremia (30.3%), hyperchloremia (10.7%), glycosuria (11.50%), hypercreatininemia (40.2%) and hypoglycemia (15.6%) were frequent and significantly (p < 0.05) higher among hypertensive individuals as compared to normotensive participants. Hypertensive patients showed low levels of hepatic metabolic abnormalities. Of the 244 hypertensive patients, 40% are complicated by various forms of metabolic abnormalities. Conclusion: Overall, the results of the present study indicate that genetic and behavioral parameters as well as cardiac and renal metabolic disturbances are the main risk factors of hypertension in the study population. Hence, strategies targeting the metabolic pathways may be therapeutic options for improving biochemical abnormalities and reducing blood pressure and risk of complications in metabolic hypertension.

Keywords:
hypertension prevalence risk factors metabolic abnormalities

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet 2017; 389(10064): 37-55.
[2]	WHO (World Health Organization). A global brief on hypertension: silent killer, global public health crisis: World Health Day 2013. Geneva: WHO, 2013.
[3]	WHO Steps Manual. International Society of Nephrology: Program for detection and management of chronic kidney disease, hypertension, diabetes and cardiovascular disease in developing countries (KHDC PROGRAM). Brussels, Int Soci Nephrol. 2005; 17-19.
[4]	Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004; 22(1):11-9.
[5]	Zhu Z, Wang P, Ma S. Metabolic hypertension: concept and practice. Front. Med. 2013; 7(2): 201-206.
[6]	World Health Organization, Global Status Report on Noncommunicable Diseases 2010, World Health Organization, Geneva, Switzerland, 2011.
[7]	Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. β-Adrenergic receptor blockers and weight gain. A systematic analysis. Hypertension 2001; 37: 250-254.
[8]	Boschmann M, Engeli S, Adams F, Franke G. Influences of AT1 receptor blockade on tissue metabolism in obese men. Am. J. Physiol. Regul. Integr. Com. Physiol. 2006; 290: R219-R223.
[9]	Mathai ML, Naik S, Sinclair AJ, Weisinger HS. Weisinger RS. Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats. Int. J. Obes. 2008; 32: 1576-1584.
[10]	Chu S, Zhu D, Xiong M. Linkage analysis of candidate genes for glucose and lipid metabolism with essential hypertension. Nation Med J China (Zhonghua Yi Xue Za Zhi) 2001; 81(1): 20-22.
[11]	Xu XS, Yang WT, Liu DY, Zhong J, Tian ZQ, Yan ZC, Ni YX, Chen J, Zhao ZG, Zhu ZM. Cardiovascular and Renal Damage in Hypertensive Complicated with Metabolic Disorders. Chin J Hypertens (Zhonghua Gao Xue Ya Za Zhi) 2006; 14(11): 894-898.
[12]	Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37(4): 1053-1059.
[13]	Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation. 2005; 112(5): 666-673.
[14]	Tanaka M, Itoh H. Hypertension as a Metabolic Disorder and the Novel Role of the Gut. Curr Hypertens Rep 2019; 21: 63.
[15]	Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-densitylipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
[16]	Lee SR, Cha MJ, Kang DY, Oh KC, Shin DH, Lee HY. Increased prevalence of metabolic syndrome among hypertensive population Ten years’ trend of the Korean National Health and Nutrition Examination Survey. Int J Cardiol 2013; 166(3): 633-639.
[17]	Borzecki A, Glickman M, Kader B, Berlowitz D. The effect of age on hypertension control and management,” Am J Hypertens 2006; 19(5): 520-527.
[18]	Manimunda SP, Sugunan AP, Benegal V, Balakrishna N, Rao MV, Pesala KS. Association of hypertension with risk factors & hypertension related behaviour among the aboriginal nicobarese tribe living in car nicobar island. India. Indian J Med Res 2011; 133(3): 287-293.
[19]	Mahmood SE, Srivastava A, Shrotriya VP, Shaifali I, Mishra P, Prevalence and epidemiological correlates of hypertension among labour population, Nat J Community Med 2011;2(1): 43-48.
[20]	Laxmaiah A, Meshram II, Arlappa N, Balakrishna N, Rao KM, Reddy ChG, Ravindranath M, Kumar S, Kumar H, Brahmam GN. Socio-economic & demographic determinants of hypertension & knowledge, practices & risk behaviour of tribal in India, Indian J Med Res 2015; 141(5): 697-708.
[21]	Awino BO, Ogonda LA, Barno G. C, Ng’wena GM. Awareness status and associated risk factors for hypertension among adult patients attending yala sub-county hospital, siaya county, Kenya. Public Health Res 2016; 6(4): 99-105.
[22]	Krzesinski J. Epidémiologie de l’hypertension artérielle. Rev Med Liege 2002 ;57(3): 142-47.
[23]	Belmin J. Actualités sur l’hypertension artérielle. L’hypertension du sujet âgé. Presse Med 1999 ;28(16): 862-869.
[24]	Llyod-Jones D, Evanx J, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. J Am Med Assoc 2005; 294(4): 466-472.
[25]	Nielsen G, Andersen L. The association between high blood pressure, physical fitness, and body mass index inadolescents. Prev Med 2003; 36(2): 229-234.
[26]	Fagard R. Physical activity, physical fitness and the incidence of hypertension. J Hypertens 2005; 23(2): 265-267.
[27]	Cornelissen V, Fagard R. Effects of endurance training on blood pressure, blood pressure - regulating mechanisms, and cardiovascular risk factors. Hypertension 2005; 46(4): 667-675.
[28]	Saha M, Sana N, Ranajit K. Serum lipid profile of hypertensive patients in the northern region of Bangladesh. J Biosci 2006; 14: 93-98.
[29]	Arakawa K. Effect of exercise on hypertension and associated complications. Hypertens Res 1996;19(1): 87-91.
[30]	Longo-Mbenza B. Diabète sucré et maladies cardiovasculaires. Cardiol Trop 1995; 21(82): 37-44.
[31]	Landsberg L, Aronne L, Beilin L, Burke V, Igel L, Lloyd-Jones D, Sowers J. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment. J Clin Hypertens 2013; 15: 14-33.
[32]	Kannel W. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13: 3S-10S.
[33]	Moor AVJ, Amougou S, Ombotto S, Ntone F, Wouamba D, Nonga B. Dyslipidemia in Patients with a Cardiovascular Risk and Disease at the University Teaching Hospital of Yaoundé, Cameroon. Int J Vasc Med 2017; Article ID 6061306.
[34]	Hackam D, Khan N, Padwal R, Tobe S. Primary prevention of CVD: treating hypertension. BMJ Clin Evid 2010; 1-21.
[35]	McCullough P, Li S, Jurkovitz C, Stevens L, Wang C, Collins A, Chen S, Norris KC, McFarlane S, Johnson B, Shlipak M, Obialo C, Brown W, Vassalotti J, Whaley-Connell A. CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 2008; 51(2): S38-45.
[36]	Wright R, Frier B. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev 2008; 24: 353-363.
[37]	Stranges S, Wu T, Dorn JM, Freudenheim JL, Muti P, Farinaro E, Russell M, Nochajski TH, Trevisan M. Relationship of Alcohol Drinking Pattern to Risk of Hypertension: A Population-Based Study. Hypertension 2004; 44(6): 813-819.
[38]	Aguilera M, de la Sierra A, Coca A, Estruch R, Fernández-Solá J, Urbano-Márquez A. Effect of alcohol abstinence on blood pressure: assessment by 24-hour ambulatory blood pressure monitoring. Hypertension 1999; 33(2): 653-657.
[39]	Eman M, Gordon A. Dietary fruits and vegetables and cardiovascular diseases risk. Crit Rev Food Sci Nutr 2015; 57(9): 1950-1962.
[40]	Bell J, Sabia S, Singh-Manoux A, Hamer M, Kivimaki M. Healthy obesity and risk of accelerated functional decline and disability. Int J Obes 2017; 41: 866-872.
[41]	Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 2003; 11(11): 1278-1289.
[42]	Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 2006; 22(6): 423-436.
[43]	Milicevic Z, Raz I, Beattie SD, Campaigne BN, Sarwat S, Gromniak E, Kowalska I, Galic E, Tan M, Hanefeld M. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care 2008; 31(2): S155-160.
[44]	Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 2009; 53(5): S35-S42.
[45]	Gao L, Mann GE. Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc Res 2009; 82(1): 9-20.
[46]	Razani B, Chakravarthy MV, Semenkovich CF. Insulin resistance and atherosclerosis. Endocrinol Metab Clin North Am 2008; 37(3): 603-621.